| Shared Expertise and Insights as an RDC Company at Asia’s Largest Clinical Trial Conference Last Month
| Expanding with Maven Clinical Cloud, Strengthening Position as a RDC Leader
| 2024 JNPMEDI CONNECT on November 22
(JNPMEDI CEO Kwunho Jeong is presenting at the ‘Application of Digital Solutions in Clinical Trials’ session during ‘KIC 2024’ last month)
JNPMEDI, leading innovation of the global clinical trial industry is getting an attention.
Clinical trial consulting and platform company, JNPMEDI (CEO Kwunho Jeong) participated in the ‘2024 KoNECT-MOHW-MFD International Conference (KIC 2024)’, Asia’s largest clinical trial conference, held from October 29th to 31st.
As an RDC (Research, Development, and Commercialization) company providing end-to-end services encompassing early-stage consulting for drug and medical device development, regulatory approvals, clinical trials, commercialization, and post-market management, JNPMEDI shared its expertise and insights. Additionally, it highlighted its role as an investment company based on a life sciences fund, directly investing in pharmaceutical and medical device companies while offering investor matching and licensing services.
On October 29, JNPMEDI Vice President Soohyun Lew, chaired the Vendor Management session at the 2024 KoNECT-MOHW-MFDS International Conference (KIC 2024), discussed effective vendor management strategies for global clinical trials. On October 31st, CEO Kwunho Jeong led the ‘Application of Digital Solutions in Clinical Trials session’, highlighting the transformative impact of digital solutions on clinical trials.
Reflecting on the event, CEO Jeong remarked, “KIC 2024 was an excellent opportunity to discuss the present and future of the evolving clinical trial landscape. Integrating digital technologies based on large language models (LLMs) enhances clinical trial data and document management. By leveraging the advanced capabilities of LLM-based AI, we aim to pioneer improved outcomes in operational efficiency, data integrity, and regulatory compliance for clinical trials.”
This year, JNPMEDI has continued to expand its business scope using its Maven Clinical Cloud platform, offering services in investment, clinical trial outsourcing (CRO), and commercialization consulting for pharmaceutical and medical device companies. These efforts solidify its position as a leading RDC (Research, Development, and Commercialization) company.
As part of its initiatives, JNPMEDI will host the 3rd annual 2024 JNPMEDI CONNECT on November 22 at the Grand Ballroom of The Plaza Hotel in Seoul. The event will facilitate in-depth discussions on practical strategies and the latest technologies in the RDC sector, offering a structured approach to addressing key challenges at each stage of the clinical trial process. Beyond information sharing, the event aims to foster innovation, identify solutions, and create collaboration opportunities across the industry.
The event’s academic organizing committee will be chaired by Dr. Ilseop Lee, Director of the Future Medicine Research Institute at Bundang CHA Hospital. The committee also includes prominent figures such as Daehee Lee, CEO of Seoul CRO; Hanlim Moon, CEO of MediRama; and Hyungjin Jung, Executive Director at Janssen Korea. Notable speakers include Kyunghwa Huh, CEO of KIMCo, and Daeyoung Jung, Senior Manager at LigaChem Bio, who will deliver presentations and engage in panel discussions.
Open to professionals in the pharmaceutical, biotech, and medical device industries, as well as those with an interest in related fields, the event offers pre-registration through the official 2024 JNPMEDI CONNECT website. Pre-registered attendees will also have a chance to participate in a lucky draw event.
“Our proprietary clinical trial solution, Maven Clinical Cloud, has enabled us to steadily expand our business across diverse medical sectors this year,” CEO Jeong noted. “The upcoming 2024 JNPMEDI CONNECT will be a platform to showcase our achievements to domestic and international clinical research experts and related companies. It will also serve as a venue to promote innovative growth for Korean biotech companies and their entry into the global market.”
| Shared Expertise and Insights as an RDC Company at Asia’s Largest Clinical Trial Conference Last Month
| Expanding with Maven Clinical Cloud, Strengthening Position as a RDC Leader
| 2024 JNPMEDI CONNECT on November 22
(JNPMEDI CEO Kwunho Jeong is presenting at the ‘Application of Digital Solutions in Clinical Trials’ session during ‘KIC 2024’ last month)
JNPMEDI, leading innovation of the global clinical trial industry is getting an attention.
Clinical trial consulting and platform company, JNPMEDI (CEO Kwunho Jeong) participated in the ‘2024 KoNECT-MOHW-MFD International Conference (KIC 2024)’, Asia’s largest clinical trial conference, held from October 29th to 31st.
As an RDC (Research, Development, and Commercialization) company providing end-to-end services encompassing early-stage consulting for drug and medical device development, regulatory approvals, clinical trials, commercialization, and post-market management, JNPMEDI shared its expertise and insights. Additionally, it highlighted its role as an investment company based on a life sciences fund, directly investing in pharmaceutical and medical device companies while offering investor matching and licensing services.
On October 29, JNPMEDI Vice President Soohyun Lew, chaired the Vendor Management session at the 2024 KoNECT-MOHW-MFDS International Conference (KIC 2024), discussed effective vendor management strategies for global clinical trials. On October 31st, CEO Kwunho Jeong led the ‘Application of Digital Solutions in Clinical Trials session’, highlighting the transformative impact of digital solutions on clinical trials.
Reflecting on the event, CEO Jeong remarked, “KIC 2024 was an excellent opportunity to discuss the present and future of the evolving clinical trial landscape. Integrating digital technologies based on large language models (LLMs) enhances clinical trial data and document management. By leveraging the advanced capabilities of LLM-based AI, we aim to pioneer improved outcomes in operational efficiency, data integrity, and regulatory compliance for clinical trials.”
This year, JNPMEDI has continued to expand its business scope using its Maven Clinical Cloud platform, offering services in investment, clinical trial outsourcing (CRO), and commercialization consulting for pharmaceutical and medical device companies. These efforts solidify its position as a leading RDC (Research, Development, and Commercialization) company.
As part of its initiatives, JNPMEDI will host the 3rd annual 2024 JNPMEDI CONNECT on November 22 at the Grand Ballroom of The Plaza Hotel in Seoul. The event will facilitate in-depth discussions on practical strategies and the latest technologies in the RDC sector, offering a structured approach to addressing key challenges at each stage of the clinical trial process. Beyond information sharing, the event aims to foster innovation, identify solutions, and create collaboration opportunities across the industry.
The event’s academic organizing committee will be chaired by Dr. Ilseop Lee, Director of the Future Medicine Research Institute at Bundang CHA Hospital. The committee also includes prominent figures such as Daehee Lee, CEO of Seoul CRO; Hanlim Moon, CEO of MediRama; and Hyungjin Jung, Executive Director at Janssen Korea. Notable speakers include Kyunghwa Huh, CEO of KIMCo, and Daeyoung Jung, Senior Manager at LigaChem Bio, who will deliver presentations and engage in panel discussions.
Open to professionals in the pharmaceutical, biotech, and medical device industries, as well as those with an interest in related fields, the event offers pre-registration through the official 2024 JNPMEDI CONNECT website. Pre-registered attendees will also have a chance to participate in a lucky draw event.
“Our proprietary clinical trial solution, Maven Clinical Cloud, has enabled us to steadily expand our business across diverse medical sectors this year,” CEO Jeong noted. “The upcoming 2024 JNPMEDI CONNECT will be a platform to showcase our achievements to domestic and international clinical research experts and related companies. It will also serve as a venue to promote innovative growth for Korean biotech companies and their entry into the global market.”